What's breaking now, across thousands of outlets.
(MedPage Today) -- The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance mutations during first-line treatment. Camizestrant...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.
Researchers found that altering a small group of dopamine-producing neurons in fruit flies fragments their sleep. This sleep deprivation prevents the insects from forming long-term memories…
A team from the Research Institute of the McGill University Health Center (The Institute) have created a three-dimensional, beating heart-on-a-chip, or "mini-heart," using blood cells from a patient…
Rather than requiring genetic modification of the viral glycoprotein, G-Link uses a modular protein adaptor to blind native VSV-G tropism and redirect delivery after vector production.
IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.
Researchers from Cambridge and Basel have developed small molecules that could make cancer immunotherapies more effective.
